ApexOnco Front Page Recent articles 17 March 2025 Astra gives in vivo Car-T its biggest endorsement The company buys Belgium’s EsoBiotec for $425m. 17 March 2025 Otsuka bids for a seat at the conjugate table The acquisition of Araris follows a 2023 discovery collaboration. 16 September 2024 ESMO 2024 – Scorpion joins Relay in the alpha club What Relay managed with a combo Scorpion might be able to do with STX-478 monotherapy. 15 September 2024 ESMO 2024 – J&J eyes Rybrevant colorectal expansion Early data on Rybrevant plus chemo have spurred a quick leap into pivotal trials. 15 September 2024 ESMO 2024 – changing FDA stance could haunt Astra’s Niagara win Niagara looks sound, but how much benefit did Imfinzi contribute to each of its two settings? 15 September 2024 ESMO 2024 – Keytruda/Lenvima leap... up to a point Leap-012 delivers a technical win, but filing might hinge on overall survival and a call on toxicity. 15 September 2024 ESMO 2024 – a role for immunotherapy in ovarian cancer If the therapeutic window remains open, OncoC4/BioNTech’s gotistobart could hold promise. 15 September 2024 ESMO 2024 – combos could be the way forward for CDK2 Incyte’s first substantial data with INCB123667 are eclipsed by Pfizer’s PF-07104091/atirmociclib combo. Load More Recent Quick take Blueprint raises Ayvakit expectations 15 February 2024 Roche runs from Repare 13 February 2024 Foghorn gets an all-clear from Lilly 12 February 2024 After Dreamm-7, how about more multiple myeloma conjugates? 9 February 2024 Astra's next wave goes beyond subcutaneous Imfinzi 8 February 2024 BioNTech bails out Autolus 8 February 2024 Jazz joins the KRAS band with Redx deal 7 February 2024 Gilead deals more checkpoint disappointment 7 February 2024 The pullback from RET inhibition 6 February 2024 Bristol shows its alnuctamab hand 5 February 2024 Load More Most Popular